Latest Insulin glargine Stories
Surveyed German Nephrologists Report that the Majority of Their Patients Treated with Epoetin Alfa Receive a Biosimilar, According to Findings from Decision Resources Group BURLINGTON, Mass.,
BRIDGEWATER, N.J., Oct.
Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc.
Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept.
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S.
- Toujeo dossier already accepted by EMA - PARIS, July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human
AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia SAN FRANCISCO, June 16, 2014
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
- To swell, as grain or wood with water.